FL1
MCID: FLL041
MIFTS: 50

Follicular Lymphoma 1 (FL1)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma 1

MalaCards integrated aliases for Follicular Lymphoma 1:

Name: Follicular Lymphoma 1 57 29
Follicular Lymphoma, Susceptibility to, 1 57 13
Lymphoma, Follicular, Type 1 40
Lymphoma, Follicular 72
Follicular Lymphoma 59
Fl1 57

Characteristics:

Orphanet epidemiological data:

59
follicular lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

OMIM 57 613024
MESH via Orphanet 45 D008224
UMLS via Orphanet 73 C0024301
Orphanet 59 ORPHA545
MedGen 42 C2751665
UMLS 72 C0024301

Summaries for Follicular Lymphoma 1

OMIM : 57 Follicular non-Hodgkin lymphoma is an indolent B-cell malignancy with an annual incidence exceeding 10,000 cases in the United States (Bohen et al., 2003). One form of susceptibility to follicular lymphoma (FL1) is associated with a region on chromosome 6p21.33. (613024)

MalaCards based summary : Follicular Lymphoma 1, also known as follicular lymphoma, susceptibility to, 1, is related to follicular lymphoma and lymphoma. An important gene associated with Follicular Lymphoma 1 is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Immune response NFAT in immune response and Direct p53 effectors. The drugs Entecavir and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are lymphoma and splenomegaly

Related Diseases for Follicular Lymphoma 1

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 431)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 31.7 BCL6 BCL2 BCL10
2 lymphoma 31.6 BCL6 BCL2 BCL10
3 diffuse large b-cell lymphoma 31.5 BCL6 BCL10
4 nodal marginal zone b-cell lymphoma 31.3 BCL6 BCL2
5 primary central nervous system lymphoma 31.1 BCL6 BCL2
6 mantle cell lymphoma 30.9 IGH BCL6 BCL2
7 intravascular large b-cell lymphoma 30.5 BCL6 BCL2
8 marginal zone b-cell lymphoma 30.4 BCL6 BCL2 BCL10
9 t-cell/histiocyte rich large b cell lymphoma 30.3 IGH BCL6
10 lymphoma, non-hodgkin, familial 29.9 IGH BCL6 BCL2 BCL10
11 leukemia, chronic lymphocytic 29.5 IGH BCL6 BCL2 BCL10
12 precursor t-cell acute lymphoblastic leukemia 29.4 IGH BCL10
13 lymphoma, mucosa-associated lymphoid type 29.3 IGH BCL6 BCL2 BCL10
14 primary cutaneous follicle center lymphoma 11.9
15 histiocytic and dendritic cell cancer 11.6
16 burkitt lymphoma 11.1
17 b-cell lymphoma 11.0
18 lymphoblastic lymphoma 10.9
19 primary effusion lymphoma 10.9
20 lymphomatoid granulomatosis 10.9
21 splenic marginal zone lymphoma 10.9
22 leukemia, acute lymphoblastic 3 10.8
23 lymphoma, hodgkin, classic 10.8
24 plasmablastic lymphoma 10.8
25 diffuse large b-cell lymphoma of the central nervous system 10.8
26 lymphocytic leukemia 10.7
27 leukemia, b-cell, chronic 10.6
28 neutropenia 10.6
29 hematopoietic stem cell transplantation 10.5
30 myelodysplastic syndrome 10.4
31 b-cell non-hodgkin lymphoma 10.4
32 lymphosarcoma 10.4
33 splenomegaly 10.4
34 nodal marginal zone lymphoma 10.4
35 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4
36 primary cutaneous marginal zone b-cell lymphoma 10.4
37 alk-positive large b-cell lymphoma 10.4
38 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 10.4
39 splenic diffuse red pulp small b-cell lymphoma 10.4
40 diffuse large b-cell lymphoma with chronic inflammation 10.4
41 lymphoplasmacytic lymphoma without igm production 10.4
42 primary mediastinal large b-cell lymphoma 10.4
43 chromosomal triplication 10.4
44 leukemia, acute lymphoblastic 10.3
45 myeloma, multiple 10.3
46 leukemia, acute myeloid 10.3
47 graft-versus-host disease 10.3
48 lymphoproliferative syndrome 10.3
49 leukemia 10.3
50 composite lymphoma 10.3

Graphical network of the top 20 diseases related to Follicular Lymphoma 1:



Diseases related to Follicular Lymphoma 1

Symptoms & Phenotypes for Follicular Lymphoma 1

Human phenotypes related to Follicular Lymphoma 1:

59 32 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphoma 59 32 Very frequent (99-80%) HP:0002665
2 splenomegaly 59 Frequent (79-30%)
3 fever 59 Very frequent (99-80%)
4 fatigue 59 Frequent (79-30%)
5 weight loss 59 Very frequent (99-80%)
6 lymphedema 59 Occasional (29-5%)
7 meningitis 59 Occasional (29-5%)
8 mediastinal lymphadenopathy 59 Very frequent (99-80%)
9 lymphadenopathy 59 Very frequent (99-80%)
10 abnormality of the peritoneum 59 Occasional (29-5%)
11 pleural effusion 59 Occasional (29-5%)
12 skin nodule 59 Occasional (29-5%)
13 night sweats 59 Very frequent (99-80%)

Clinical features from OMIM:

613024

Drugs & Therapeutics for Follicular Lymphoma 1

Drugs for Follicular Lymphoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 483)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
7 Orange Approved Phase 3
8
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
9
Ribavirin Approved Phase 3 36791-04-5 37542
10
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
11
Ifosfamide Approved Phase 3 3778-73-2 3690
12
Teniposide Approved Phase 3 29767-20-2 34698
13
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
16
Dalteparin Approved Phase 3 9005-49-6
17
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Ofloxacin Approved Phase 3 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
21
Idarubicin Approved Phase 3 58957-92-9 42890
22
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
23
Tazobactam Approved Phase 3 89786-04-9 123630
24
Piperacillin Approved Phase 3 66258-76-2 43672
25
Vancomycin Approved Phase 3 1404-90-6 441141 14969
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
28
Captopril Approved Phase 3 62571-86-2 44093
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
31
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
32
Morphine Approved, Investigational Phase 3 57-27-2 5288826
33
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
34
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
35
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
36
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
37
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
38
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
39
ofatumumab Approved Phase 3 679818-59-8 6918251
40
Idelalisib Approved Phase 3 870281-82-6
41
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
leucovorin Approved Phase 3 58-05-9 143 6006
44
Pixantrone Approved, Investigational Phase 3 144510-96-3
45
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
46
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
47
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
48
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
49
Polyestradiol phosphate Approved Phase 3 28014-46-2
50
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4

Interventional clinical trials:

(show top 50) (show all 1174)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
4 A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma Recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine
5 Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
6 Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
8 Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
9 MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA Unknown status NCT00435955 Phase 3 Rituximab
10 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
11 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
12 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
13 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
14 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
15 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
16 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
17 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
19 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
20 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
21 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
22 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
23 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
24 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
25 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
26 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
27 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Completed NCT02213263 Phase 3
28 FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden Completed NCT00136552 Phase 3 rituximab
29 Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy Completed NCT00140582 Phase 3 Rituximab
30 A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma Completed NCT02162771 Phase 3 Cyclophosphamide;Vincristine;Prednisone
31 A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen Completed NCT02569996 Phase 3 Rituximab
32 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
33 Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial Completed NCT00227695 Phase 3
34 A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
35 Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden Completed NCT00696735 Phase 3
36 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
37 A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
38 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
39 Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial Completed NCT00185393 Phase 3
40 Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
41 Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
42 A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV Completed NCT01200758 Phase 3 Rituximab SC;Rituximab IV;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone/Prednisolone
43 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
44 Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
45 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
46 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
47 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
48 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
49 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
50 Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study Completed NCT00004179 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate

Search NIH Clinical Center for Follicular Lymphoma 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Chlorambucil
ibritumomab tiuxetan
Ibritumomab tiuxetan

Genetic Tests for Follicular Lymphoma 1

Genetic tests related to Follicular Lymphoma 1:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 1 29

Anatomical Context for Follicular Lymphoma 1

MalaCards organs/tissues related to Follicular Lymphoma 1:

41
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Liver

Publications for Follicular Lymphoma 1

Articles related to Follicular Lymphoma 1:

(show all 28)
# Title Authors PMID Year
1
Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. 8
23791106 2013
2
Integrating GWAS and expression data for functional characterization of disease-associated SNPs: an application to follicular lymphoma. 8
23246294 2013
3
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. 8
20639881 2010
4
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. 8
19620980 2009
5
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. 8
12571354 2003
6
BCL2 translocation frequency rises with age in humans. 8
8090743 1994
7
bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. 8
2648153 1989
8
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. 8
3287162 1988
9
The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. 8
2965608 1988
10
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. 8
3110950 1987
11
Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. 8
3537802 1987
12
Involvement of the bcl-2 gene in human follicular lymphoma. 8
3874430 1985
13
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. 8
6334305 1984
14
Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. 8
6605167 1983
15
Mapping of an endogenous retroviral sequence to human chromosome 18. 8
6843662 1983
16
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. 8
7133054 1982
17
Use of Smooth Muscle Myosin Heavy Chain as an Effective Marker of Follicular Dendritic Cells. 38
28549038 2019
18
Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. 38
29086453 2018
19
The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. 38
26352106 2016
20
Primary gastrointestinal lymphomas - A study of 81 Cases from a Tertiary Healthcare Centre. 38
25494124 2014
21
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. 38
22496164 2012
22
Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. 38
21736867 2012
23
[Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. 38
20079011 2009
24
Expression of p63 in reactive hyperplasias and malignant lymphomas. 38
16224147 2005
25
Extranodal malignant lymphoma of the upperaerodigestive tract in King Chulalongkorn Memorial Hospital according to WHO classification. 38
16083197 2004
26
[Primary gastric lymphoma]. 38
15483686 2004
27
Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer. 38
12400605 2002
28
Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia. 38
1101936 1975

Variations for Follicular Lymphoma 1

ClinVar genetic disease variations for Follicular Lymphoma 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10): c.427_428dup (p.Glu145fs) duplication Pathogenic rs587776632 1:85733584-85733585 1:85267901-85267902
2 BCL10 NM_003921.5(BCL10): c.231dup (p.Gly78fs) duplication Pathogenic rs587776633 1:85736416-85736416 1:85270733-85270733
3 BCL10 NM_003921.5(BCL10): c.525_541del (p.Val176fs) deletion Pathogenic rs587776634 1:85733471-85733487 1:85267788-85267804
4 BCL10 NM_003921.5(BCL10): c.410del (p.Asn137fs) deletion Pathogenic rs587776635 1:85733602-85733602 1:85267919-85267919
5 BCL10 NM_003921.5(BCL10): c.398dup (p.Ser134fs) duplication Pathogenic rs587776636 1:85733614-85733614 1:85267931-85267931
6 BCL10 NM_003921.5(BCL10): c.629_631AAG[2] (p.Glu212del) short repeat Pathogenic rs587776637 1:85733375-85733377 1:85267692-85267694

Expression for Follicular Lymphoma 1

Search GEO for disease gene expression data for Follicular Lymphoma 1.

Pathways for Follicular Lymphoma 1

GO Terms for Follicular Lymphoma 1

Biological processes related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.5 HLA-DRB1 BCL6 BCL10
2 T cell receptor signaling pathway GO:0050852 9.4 HLA-DRB1 BCL10
3 negative regulation of cell growth GO:0030308 9.37 BCL6 BCL2
4 B cell differentiation GO:0030183 9.26 BCL6 BCL2
5 cell morphogenesis GO:0000902 9.16 BCL6 BCL2
6 positive regulation of B cell proliferation GO:0030890 8.96 BCL6 BCL2
7 regulation of apoptotic process GO:0042981 8.8 BCL6 BCL2 BCL10

Molecular functions related to Follicular Lymphoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 BCL2 BCL10

Sources for Follicular Lymphoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....